Athersys, Inc. (NASDAQ:ATHX) is reporting third quarter earnings results on Monday 9th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.09 per share.
For the full year, analysts predict revenues of $ 0.41 million, while looking forward to loss of $ 0.36 per share.
Previous Quarter Performance
Athersys, Inc. posted loss for the second quarter of $ 0.10 per share, from the revenue of $ 0.08 million. The quarterly revenues down 98.12 percent compared with the same quarter last year. According to street consensus, ATHX was expected to report 2Q20 loss of $ 0.08 per share from revenue of $ 1.06 million. The bottom line results missed street analysts by $ 0.02 or 25 percent, at the same time, top line results fell short of analysts by $ 0.98 million or 92.45 percent.
Stock Performance
On Friday, shares of Athersys, Inc. has traded high as $ 1.82 and has cracked $ 1.72 on the downward trend, reaching $ 1.76 with volume of 859.60 thousand shares.
According to the previous trading day, closing price of $ 1.76, representing a 60.18 % increase from the 52 week low of $ 1.13 and a 58.68 % decrease over the 52 week high of $ 4.38.
The company has a market capital of $ 347.43 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Athersys, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.athersys.com
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The companys lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers.
